Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bogner

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Nature Medicine|July 7, 2014
A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese miceDa Young Oh, Evelyn Walenta, Taro E Akiyama, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 23, 2019
<i>N</i>-acetylaspartate availability is essential for juvenile survival on fat-free diet and determines metabolic healthDina C Hofer, Gabriel Zirkovits, Helmut J Pelzmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialI Ray-Coquard, A Leary, S Pignata, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Nature Medicine|July 7, 2014
A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese miceDa Young Oh, Evelyn Walenta, Taro E Akiyama, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 23, 2019
<i>N</i>-acetylaspartate availability is essential for juvenile survival on fat-free diet and determines metabolic healthDina C Hofer, Gabriel Zirkovits, Helmut J Pelzmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialI Ray-Coquard, A Leary, S Pignata, et al.
Pageof 5